Louise Chen
Stock Analyst at Cantor Fitzgerald
(3.82)
# 700
Out of 4,650 analysts
281
Total ratings
57.56%
Success rate
5.78%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Reiterates: Overweight | $45 | $28.86 | +55.93% | 30 | Oct 25, 2024 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $32.54 | - | 7 | Oct 25, 2024 | |
| JNJ Johnson & Johnson | Reiterates: Overweight | $215 | $161.60 | +33.04% | 40 | Oct 16, 2024 | |
| ZVRA Zevra Therapeutics | Reiterates: Overweight | n/a | $8.05 | - | 5 | Oct 11, 2024 | |
| NVO Novo Nordisk | Reiterates: Overweight | $160 | $112.36 | +42.40% | 19 | Oct 10, 2024 | |
| MRK Merck & Co. | Reiterates: Overweight | $155 | $104.23 | +48.71% | 25 | Oct 3, 2024 | |
| ROIV Roivant Sciences | Reiterates: Overweight | n/a | $11.84 | - | 9 | Sep 19, 2024 | |
| LLY Eli Lilly | Reiterates: Overweight | $885 | $895.59 | -1.18% | 45 | Sep 16, 2024 | |
| EOLS Evolus | Reiterates: Overweight | n/a | $16.27 | - | 5 | Sep 16, 2024 | |
| IMVT Immunovant | Reiterates: Overweight | n/a | $29.95 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.11 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.25 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.47 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.29 | - | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $189.68 | +5.44% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.93 | - | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $112.80 | - | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.45 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.90 | - | 4 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.06 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.63 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.30 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $928.61 | -0.39% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.42 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $17.49 | +271.64% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.61 | - | 4 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.26 | +296.83% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $1.19 | +2,000.84% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $20.65 | +142.13% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $8.71 | +474.05% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.57 | +219.49% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $2.84 | +216.90% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $21 | $0.67 | +3,043.71% | 3 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $67,500 | $1.13 | +5,973,351.33% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $459.29 | -43.83% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $18.37 | -18.35% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.91 | +2,517.80% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.50 | +1,233.33% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $5.90 | +747.46% | 1 | Jul 21, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $6.00 | +650.00% | 1 | Jun 22, 2017 |
Pfizer
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $28.86
Upside: +55.93%
Zai Lab
Oct 25, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.54
Upside: -
Johnson & Johnson
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $161.60
Upside: +33.04%
Zevra Therapeutics
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.05
Upside: -
Novo Nordisk
Oct 10, 2024
Reiterates: Overweight
Price Target: $160
Current: $112.36
Upside: +42.40%
Merck & Co.
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $104.23
Upside: +48.71%
Roivant Sciences
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.84
Upside: -
Eli Lilly
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $895.59
Upside: -1.18%
Evolus
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.27
Upside: -
Immunovant
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $29.95
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.11
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.25
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.47
Upside: -
Aug 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.29
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $189.68
Upside: +5.44%
Aug 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.93
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $112.80
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.45
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.90
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.06
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.63
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.30
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $928.61
Upside: -0.39%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.42
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $17.49
Upside: +271.64%
Nov 14, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.26
Upside: +296.83%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $1.19
Upside: +2,000.84%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $20.65
Upside: +142.13%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $8.71
Upside: +474.05%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.57
Upside: +219.49%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $2.84
Upside: +216.90%
May 10, 2023
Maintains: Neutral
Price Target: $33 → $21
Current: $0.67
Upside: +3,043.71%
Jul 7, 2021
Initiates: Overweight
Price Target: $67,500
Current: $1.13
Upside: +5,973,351.33%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $459.29
Upside: -43.83%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $18.37
Upside: -18.35%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.91
Upside: +2,517.80%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.50
Upside: +1,233.33%
Jul 21, 2017
Initiates: Overweight
Price Target: $50
Current: $5.90
Upside: +747.46%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $6.00
Upside: +650.00%